WASHINGTON — Adults age 65 and older face a higher risk of severe influenza and its complications. New research indicates that high-dose flu vaccines provide greater protection against hospitalization than standard-dose versions for this group.
Public health authorities continue to preferentially recommend enhanced formulations for older adults this flu season.
The question of whether adults should seek a high-dose shot has gained attention as influenza vaccination campaigns begin. Studies show the immune response to standard vaccines weakens with age. High-dose products address that decline by delivering more antigen.
Evidence from large trials
A pragmatic randomized trial in Denmark involving more than 332,000 older adults found the high-dose inactivated vaccine reduced influenza-related hospitalizations by 43.6 percent relative to the standard-dose vaccine.
Absolute risks remained low in both groups. Separate analyses of the same data set showed more modest or mixed results when the outcome combined flu and pneumonia hospitalizations.
Earlier randomized efficacy trials reported that the high-dose vaccine was about 24 percent more effective at preventing laboratory-confirmed influenza in adults 65 and older. Immunogenicity studies consistently show higher antibody levels after high-dose vaccination compared with standard-dose shots.
Researchers note that results can vary by season, circulating strains, and the exact clinical endpoint measured. One recent Spanish trial produced different findings on combined flu-or-pneumonia hospitalizations, underscoring that relative benefits are not uniform every year.
How high-dose vaccines differ
Fluzone High-Dose, manufactured by Sanofi, contains four times the hemagglutinin antigen of a standard inactivated flu vaccine. It is licensed in the United States for people 65 and older.
The higher antigen content is intended to produce a stronger immune response in older adults, whose systems typically generate fewer antibodies after standard vaccination.

The vaccine is one of three formulations the Centers for Disease Control and Prevention preferentially recommends for adults 65 and older. The others are the recombinant vaccine Flublok and the adjuvanted vaccine Fluad.
The CDC states that if none of these three is available, any age-appropriate flu vaccine should be given rather than delaying immunization.
A newer mRNA influenza vaccine, mFLUSIVA from Moderna, received FDA approval for adults 50 to 64 and accelerated approval for those 65 and older. Phase 3 data showed 26.6 percent greater protection against laboratory-confirmed flu than a standard-dose vaccine in adults 50 and older. Medical societies differ slightly on whether to include it among preferred options for the oldest adults pending additional comparative data.
Recommendations and risk groups
The CDC and several medical organizations advise that adults 65 and older receive an enhanced vaccine when available. People who have received solid-organ transplants and take immunosuppressive drugs may also be offered high-dose or other enhanced formulations as an acceptable option, even if younger than 65.
Older adults account for the majority of flu-related hospitalizations and deaths in most seasons. Conditions such as chronic lung disease further elevate risk. Vaccination remains recommended for nearly everyone 6 months and older who lacks a medical contraindication.
Side-effect profiles for high-dose vaccines are generally similar to standard-dose shots, though local reactions such as arm soreness and mild systemic symptoms can occur more frequently. Serious adverse events have not shown meaningful differences in large safety analyses.



